HIL-214 is a subunit vaccine commercialized by HilleVax, with a leading Phase II program in Gastroenteritis. According to Globaldata, it is involved in 15 clinical trials, of which 14 were completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of HIL-214s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for HIL-214 is expected to reach an annual total of $24 mn by 2039 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
HIL-214 Overview
HIL-214 is under development for the prevention of acute gastroenteritis caused by norovirus. The vaccine candidate is administered through intramuscular route as a suspension. It is a norovirus GI.1/GII 4 bivalent virus-like particle (VLP) vaccine adjuvanted with monophosphoryl lipid A (MPL) and aluminum hydroxide (AlOH). MPL increases the vaccine’s immunogenic effect.
It was under development for the prevention of acute gastroenteritis caused by norovirus.
HilleVax Overview
HilleVax is a biopharmaceutical company that develop vaccine to protect against norovirus infection. The company is headquartered in United States.
The operating loss of the company was US$65.1 million in FY2022, compared to an operating loss of US$53.4 million in FY2021. The net loss of the company was US$159.8 million in FY2022, compared to a net loss of US$102.4 million in FY2021.
For a complete picture of HIL-214s valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
